Calysta announces participation in project to test new sustainable Omega 3 source

Calysta is participating in a collaborative research project by offering to fast track the scaling up of a new microbial technology that uses microorganisms to ferment methane gas into valuable nutritional supplements. “This is a great example of how publicly funded early stage research is being leveraged and commercially exploited with an industry partner to scale up successful discoveries made in the lab.”

June 2, 2016

Researchers at The University of Nottingham’s Synthetic Biology Research Centre are working with biotechnology company CHAIN Biotech and industry partner Calysta, Inc. to develop microbial technology that uses microorganisms to ferment methane gas into valuable nutritional supplements.

The pioneering project is called PUFA (polyunsaturated fatty acids). It will run for a year and is being funded by industrial biotechnology catalyst grants from InnovateUK and the BBSRC with potential further significant scaling up investment from Calysta, a sustainable nutrition company based in the US.

Leading the research at Nottingham’s Synthetic Biology Research Centre, Professor Nigel Minton said: “We specialize in the use of fermentation of certain gases to produce sustainable industrial chemicals and biofuels and now, through this project, to produce vital feedstock ingredients like Omega 3 fatty acids. We will be engineering the Methanococcus microbe to produce polyunsaturated fatty acids from a cheap and replenishable feedstock – methane gas.

“There are huge potential benefits in terms of reducing dependency on fishing and also creating a new use for a plentiful gas that has a harmful effect on the environment if unharnessed. Methane is a low cost and sustainable feedstock that can be produced from a variety of renewable sources, including anaerobic digestion which is now prevalent in the UK and EU.”

Dr Basil Omar, Chief Commercial Officer at CHAIN Biotech Ltd said: “This is a great example of how publicly funded early stage research is being leveraged and commercially exploited with an industry partner to scale up successful discoveries made in the lab. This highly innovative project will draw upon CHAIN’s world leading expertise in Synthetic Biology to improve production characteristics by targeting both cell growth and product yield simultaneously with a focus on Omega 3 fatty acids. We hope it will offer a cheaper route to a high demand product with positive environmental and social knock on effects.”

Calysta, the project’s commercial partner, specializes in the production of microbial proteins for the commercial fish feed and livestock markets, and has developed and is commercializing a new patented product called FeedKind™ protein to provide a new sustainable fish food ingredient for the fish farming industry. The company will offer a fast track to scaling up of the PUFA manufacturing process.

Calysta is based in California and will open a market introduction facility for FeedKind in Teesside, England, later this year. A commercial-scale plant in the US is also expected to come online in 2018.

Alan Shaw, Ph.D., Calysta President and Chief Executive Officer, said:” Partnering the University of Nottingham and CHAIN Biotech in this project means we can develop the next generation of FeedKind protein.

“FeedKind protein is a natural, safe, high-quality, non-GMO protein source produced by a single cell organism, using a natural, proprietary fermentation process. By replacing fishmeal, fish oil and soy protein concentrate with a nutritious naturally occurring protein, the aquaculture industry can reduce its impact on the environment and on wild fisheries while continuing to grow to feed the world’s population.”